期刊文献+

替米沙坦对2型糖尿病大鼠肾组织MCP-1、NF-κB表达的影响 被引量:3

Effects of telmisantan on expression of monocyte chemoattractant protein-1,nuclear factor-kappa B in renal tissue of type 2 diabetic rats
下载PDF
导出
摘要 目的观察替米沙坦对2型糖尿病大鼠肾脏病变中单核巨噬细胞趋化蛋白-1(MCP-1)、核因子-κB(NF-κB)表达的影响。方法雄性Wistar大鼠30只,随机分成正常对照组(A组,n=10)和糖尿病模型组(n=20)。A组给予常规饲料;模型组给予高糖高脂饲料,4周后腹腔注射链尿佐菌素(STZ)30mg/kg,造模成功后模型组再随机分成糖尿病组(B组,n=10)和替米沙坦治疗组(C组,n=10),C组每天给予替米沙坦5mg/kg灌胃。替米沙坦干预12周后,用免疫组化法检测各组大鼠MCP-1、NF-κB在肾脏表达的变化。结果与A组比较,B、C组大鼠肾组织中MCP-1、NF-κB表达明显增加(P<0.01);C组比B组MCP-1、NF-κB表达明显降低(P<0.01)。结论2型糖尿病大鼠肾组织中MCP-1、NF-κB表达明显增加,替米沙坦可通过降低肾组织MCP-1、NF-κB表达,从而减轻肾脏的炎症反应。 Objective To investigate the effects of telmisantan on expression of monocyte chemoattraetant protein-1 (MCP-1)and nuclear factor-kappa B(NF-κB)in renal tissues of type 2 diabetic rats. Methods Thirty Wistar rats were randomly divided into two groups: normal control group( n = 10, group A)and diabetic group( n = 20). The rats were fed with standard diet in group A. The other rats were fed with high-glucose-high-fat diet. After 4 weeks, streptozotoein(30 mg/kg)was injected into abdominal cavity of the rats. Then the diabetic rats were randomly divided into 2 groups: model group( n = 10, group B)and telmisanta group( n = 10, group C). The rats in group C were given telmisantan for 12 consecutive weeks. At the end of the 12th week, the expression of MCP-1 and NF-κB in kidney was measured by immunohistochemistry. Results The expression of MCP-1 and NF-κB in group B and group C was significantly higher than that in group A(P 〈 0.01). The expression of MCP-1 and NF-κB in group C was lower than that in group B(P 〈 0.01 ). Conclusion Telmisantan could decrease the renal inflammatory reaction by reducing the expression of MCP- 1 and NF-κB in kidney of diabetic rats, which might be the mechanism of renal protective effect of telmisantan.
出处 《山西医科大学学报》 CAS 2008年第12期1075-1077,1152,共4页 Journal of Shanxi Medical University
基金 山西省回国留学人员基金资助项目(200744)
关键词 2型糖尿病 MCP-1 NF-ΚB 替米沙坦 type 2 diabetes monocyte chemoattractant protein-1 nuclear factor-kappa B telmisantan
  • 相关文献

参考文献7

  • 1Nobuyuki B, Tsutomu N, Michiko M, et al. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy [ J ]. Kidney Int, 2000,58 (4) : 684 - 690.
  • 2郭啸华,刘志红,李恒,朱加明,黎磊石.实验性2型糖尿病大鼠模型的建立[J].肾脏病与透析肾移植杂志,2000,9(4):351-355. 被引量:210
  • 3Wada T, Yokoyama H, Matsushima K, et al. Monocyte chemoattractant protein-1 :dose it play a role in diabetic nephropathy [J ] ? Nephrol Dial Transplant, 2003,18 : 457 - 459.
  • 4Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients [ J ]. Diabetes, 2005,54 (7) : 2206 - 2211.
  • 5Ha H, Yu MR, Choi YJ,et al. Role 4 high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells[J]. J Am Soc Nephml, 2002, 13: 894 - 902.
  • 6Piva R, Belardo G, Santoro MG. NF- kappaB : a stress regulated switch for cell survival [ J ]. Antioxid Redox Signal, 2006,8 (3 - 4) : 478 - 486.
  • 7Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin Ⅱ receptor antagonist with selective PPARgamma-modulating activity [ J ]. Hypertension, 2004,43(5) :993 - 1002.

二级参考文献3

  • 1Luo J,Metabolism,1998年,47卷,663页
  • 2Storlien L H,Ann NY Acad Sci,1993年,683卷,57页
  • 3Hwang I S,Hypertension,1987年,10卷,512页

共引文献209

同被引文献45

  • 1Navarro-Gonzalez JF,Mora-Fernandez C,Muros de Fuentes M,et a/.Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy[J].Nat Rev Nephrol, 2011,7(6) :727.
  • 2Navarro JF,Mora C,Maca M,et a/.Inflammatory parame- ters are independently associated with urinary albumin in type 2 diabetes mellitus[J].Am J Kidney Dis,2003,42( 1): 53-61.
  • 3Wada J,Makino H.Inflammation and the pathogenesis ofdiabetic nephropathy[J].C lin Sci (Lond), 2013,124 (3) : 139- 152.
  • 4Kang ES,'Kim HJ, Ahn CW, et a/.Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes[J].Di- abetes Res Clin Pract, 2005,69 ( 2 ) : 151-159.
  • 5Bums KD.Angiotensin ]I and its receptors in the diabetic kidney[J].Am J Kindey Dis, 2000,36 (3) : 449-467.
  • 6Walsh BH,Boylan GB,Livingstone V,et a/.C0rd blood pro- teins and multichannel-electroencephalography in hypoxic- ischemic encephalopathy[J].Pediatr Crit Care Med,2013, 14(6) : 621-630.
  • 7Benson SC,Pershadsingh HA, Ho CI,et a/.Identification of telmisartan as a unique angioresin 11 receptor antago- nist with selective PPARgamma-modulating activity [J]. Hypeitention, 2004,43 (5) : 993-1002.
  • 8Stehouwer CD,Snijder MB,Henie RJ,et a/.Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and wom- en: the hoorn study[J].Diabetes Care,2006,29 (11) :2498- 2503.
  • 9Zhang Q,Xiao XH, Li M ,et a/.Telmisartan improves kid- ney function through inhibition of the oxidative phospho- rylation pathway in diabetic rats[J]J Mol Endocrinol,2012, 49(1) :35-46.
  • 10Kurtz TW,Pravenec M.Antidiabetic mechanisms of an- giotensin-converting enzyme inhibitors and angiotensin 11 receptor antagonists:beyond the renin-angiotensin sys- tem[J].J Hypertens, 2004,22 (12) : 2253-2261.

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部